News & Insights

As evidence teams plan for 2026, expectations in rare diseases are shifting towards evidence that is carefully contextualised and clearly linked to decision-making needs. Recent guidance and industry commentary highlight the growing role of patient experience data, integrated real-world evidence, and earlier cross-functional planning, reinforcing that credibility comes from clarity and relevance rather than scale or complexity alone.

At DHT.health, we are proud to have contributed to Underserved, Overlooked: How our health systems are failing women and girls with a bleeding disorder, a powerful new report published by The Haemophilia Society (THS) which was presented to UK National Health Service leaders, Members of Parliament and broader stakeholders July 2025.

Patient Reported Outcomes in understanding lived experiences of individuals with a health condition.